550 related articles for article (PubMed ID: 32003919)
1. Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab.
Kogawa T; Fujii T; Wu J; Harano K; Fouad TM; Liu DD; Shen Y; Masuda H; Krishnamurthy S; Chavez-MacGregor M; Lim B; Murthy RK; Valero V; Tripathy D; Ueno NT
Oncologist; 2020 Jun; 25(6):e909-e919. PubMed ID: 32003919
[TBL] [Abstract][Full Text] [Related]
2. High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer.
Kogawa T; Fouad TM; Liu DD; Wu J; Shen Y; Masuda H; Fujii T; Chavez-MacGregor M; Alvarez RH; Hortobágyi GN; Valero V; Ueno NT
Oncologist; 2016 Jan; 21(1):21-7. PubMed ID: 26659222
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
[TBL] [Abstract][Full Text] [Related]
4. Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.
Takada M; Higuchi T; Tozuka K; Takei H; Haruta M; Watanabe J; Kasai F; Inoue K; Kurosumi M; Miyazaki M; Sato-Otsubo A; Ogawa S; Kaneko Y
BMC Cancer; 2013 May; 13():241. PubMed ID: 23679233
[TBL] [Abstract][Full Text] [Related]
5. Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Tibau A; López-Vilaró L; Pérez-Olabarria M; Vázquez T; Pons C; Gich I; Alonso C; Ojeda B; Ramón y Cajal T; Lerma E; Barnadas A; Escuin D
Neoplasia; 2014 Oct; 16(10):861-7. PubMed ID: 25379022
[TBL] [Abstract][Full Text] [Related]
6. Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer.
Lander EM; Rappazzo KC; Huang LC; Hu JR; Chen H; Shyr Y; Abramson VG
Oncologist; 2023 Feb; 28(2):123-130. PubMed ID: 36495309
[TBL] [Abstract][Full Text] [Related]
7. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
[TBL] [Abstract][Full Text] [Related]
8. NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2.
Fehrenbacher L; Cecchini RS; Geyer CE; Rastogi P; Costantino JP; Atkins JN; Crown JP; Polikoff J; Boileau JF; Provencher L; Stokoe C; Moore TD; Robidoux A; Flynn PJ; Borges VF; Albain KS; Swain SM; Paik S; Mamounas EP; Wolmark N
J Clin Oncol; 2020 Feb; 38(5):444-453. PubMed ID: 31821109
[TBL] [Abstract][Full Text] [Related]
9. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer.
Kim MM; Allen P; Gonzalez-Angulo AM; Woodward WA; Meric-Bernstam F; Buzdar AU; Hunt KK; Kuerer HM; Litton JK; Hortobagyi GN; Buchholz TA; Mittendorf EA
Ann Oncol; 2013 Aug; 24(8):1999-2004. PubMed ID: 23562929
[TBL] [Abstract][Full Text] [Related]
10. Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer.
Choi JH; Jeon CW; Kim YO; Jung S
Medicine (Baltimore); 2020 Nov; 99(46):e23053. PubMed ID: 33181670
[TBL] [Abstract][Full Text] [Related]
11. Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2-positive breast cancer?
Antolín S; García-Caballero L; Reboredo C; Molina A; Mosquera J; Vázquez-Boquete Á; Gallego R; Santiago MP; Concha Á; Pérez E; Calvo L; García-Caballero T
Virchows Arch; 2021 Oct; 479(4):853-857. PubMed ID: 33934230
[TBL] [Abstract][Full Text] [Related]
12. Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer.
Singer CF; Tan YY; Fitzal F; Steger GG; Egle D; Reiner A; Rudas M; Moinfar F; Gruber C; Petru E; Bartsch R; Tendl KA; Fuchs D; Seifert M; Exner R; Balic M; Bago-Horvath Z; Filipits M; Gnant M;
Clin Cancer Res; 2017 Jul; 23(14):3676-3683. PubMed ID: 28143867
[No Abstract] [Full Text] [Related]
13. Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials.
Guarneri V; Griguolo G; Miglietta F; Conte PF; Dieci MV; Girardi F
ESMO Open; 2022 Apr; 7(2):100433. PubMed ID: 35276440
[TBL] [Abstract][Full Text] [Related]
14. HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer.
Zhao J; Krishnamurti U; Zhang C; Meisel J; Wei Z; Suo A; Aneja R; Li Z; Li X
Pathol Res Pract; 2020 Nov; 216(11):153155. PubMed ID: 32871536
[TBL] [Abstract][Full Text] [Related]
15. Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer.
Chen HL; Chen Q; Deng YC
Medicine (Baltimore); 2021 Nov; 100(44):e27632. PubMed ID: 34871229
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab.
Fujita N; Enomoto Y; Inakami K; Yanagisawa T; Iguchi C; Aono T; Nomura T; Yamamoto H; Kasugai T; Shiba E
Oncology; 2020; 98(1):35-41. PubMed ID: 31574500
[TBL] [Abstract][Full Text] [Related]
17. A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.
Veeraraghavan J; De Angelis C; Mao R; Wang T; Herrera S; Pavlick AC; Contreras A; Nuciforo P; Mayer IA; Forero A; Nanda R; Goetz MP; Chang JC; Wolff AC; Krop IE; Fuqua SAW; Prat A; Hilsenbeck SG; Weigelt B; Reis-Filho JS; Gutierrez C; Osborne CK; Rimawi MF; Schiff R
Ann Oncol; 2019 Jun; 30(6):927-933. PubMed ID: 30903140
[TBL] [Abstract][Full Text] [Related]
18. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry.
Niikura N; Tomotaki A; Miyata H; Iwamoto T; Kawai M; Anan K; Hayashi N; Aogi K; Ishida T; Masuoka H; Iijima K; Masuda S; Tsugawa K; Kinoshita T; Nakamura S; Tokuda Y
Ann Oncol; 2016 Mar; 27(3):480-7. PubMed ID: 26704052
[TBL] [Abstract][Full Text] [Related]
19. HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy.
Stocker A; Hilbers ML; Gauthier C; Grogg J; Kullak-Ublick GA; Seifert B; Varga Z; Trojan A
PLoS One; 2016; 11(7):e0159176. PubMed ID: 27463363
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Lluch A; Tjulandin S; Zambetti M; Moliterni A; Vazquez F; Byakhov MJ; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Magazzù D; Heinzmann D; Steinseifer J; Valagussa P; Baselga J
Lancet Oncol; 2014 May; 15(6):640-7. PubMed ID: 24657003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]